![Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy](https://www.cell.com/cms/attachment/e46f3152-7ceb-411c-9ccc-f16d8da6d1f6/gr2.jpg)
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy
![Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2‐Amino‐7‐[4‐fluoro‐2‐(3‐pyridyl)phenyl]‐4‐methyl‐7,8‐dihydro‐6H‐quinazolin‐5‐one Oxime - Amici - 2014 - ChemMedChem - Wiley Online Library Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2‐Amino‐7‐[4‐fluoro‐2‐(3‐pyridyl)phenyl]‐4‐methyl‐7,8‐dihydro‐6H‐quinazolin‐5‐one Oxime - Amici - 2014 - ChemMedChem - Wiley Online Library](https://chemistry-europe.onlinelibrary.wiley.com/cms/asset/3b8882ff-5910-43c6-8060-bf8716dc98d7/msch001.jpg)
Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2‐Amino‐7‐[4‐fluoro‐2‐(3‐pyridyl)phenyl]‐4‐methyl‐7,8‐dihydro‐6H‐quinazolin‐5‐one Oxime - Amici - 2014 - ChemMedChem - Wiley Online Library
![Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2‐Amino‐7‐[4‐fluoro‐2‐(3‐pyridyl)phenyl]‐4‐methyl‐7,8‐dihydro‐6H‐quinazolin‐5‐one Oxime - Amici - 2014 - ChemMedChem - Wiley Online Library Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2‐Amino‐7‐[4‐fluoro‐2‐(3‐pyridyl)phenyl]‐4‐methyl‐7,8‐dihydro‐6H‐quinazolin‐5‐one Oxime - Amici - 2014 - ChemMedChem - Wiley Online Library](https://chemistry-europe.onlinelibrary.wiley.com/cms/asset/c974f8e4-155a-4496-95fa-0ef8b6548e99/mfig004.jpg)
Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2‐Amino‐7‐[4‐fluoro‐2‐(3‐pyridyl)phenyl]‐4‐methyl‐7,8‐dihydro‐6H‐quinazolin‐5‐one Oxime - Amici - 2014 - ChemMedChem - Wiley Online Library
![Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study | SpringerLink Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00415-018-8816-9/MediaObjects/415_2018_8816_Fig1_HTML.gif)
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study | SpringerLink
![Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy](https://www.cell.com/cms/attachment/5bae4dff-da23-4111-a60c-25201932bc78/fx1.jpg)
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy
![Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study | BMC Neurology | Full Text Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study | BMC Neurology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12883-022-02554-z/MediaObjects/12883_2022_2554_Fig2_HTML.png)
Criteria for identification of advanced Parkinson's disease: the results of the Italian subgroup of OBSERVE-PD observational study | BMC Neurology | Full Text
![Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy: Molecular Therapy](https://www.cell.com/cms/attachment/fbfbdf99-7ddf-4b22-b2f1-699811b16bc9/gr1_lrg.jpg)